ATE476176T1 - Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung - Google Patents

Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung

Info

Publication number
ATE476176T1
ATE476176T1 AT08743631T AT08743631T ATE476176T1 AT E476176 T1 ATE476176 T1 AT E476176T1 AT 08743631 T AT08743631 T AT 08743631T AT 08743631 T AT08743631 T AT 08743631T AT E476176 T1 ATE476176 T1 AT E476176T1
Authority
AT
Austria
Prior art keywords
sustained
tablets containing
release tablets
containing wax
pellets
Prior art date
Application number
AT08743631T
Other languages
English (en)
Inventor
Andrew Chen
Patricia Kigin
Original Assignee
Farnam Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farnam Co Inc filed Critical Farnam Co Inc
Application granted granted Critical
Publication of ATE476176T1 publication Critical patent/ATE476176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Agronomy & Crop Science (AREA)
  • Nutrition Science (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08743631T 2007-03-02 2008-02-29 Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung ATE476176T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90445607P 2007-03-02 2007-03-02
PCT/US2008/055534 WO2008109462A2 (en) 2007-03-02 2008-02-29 Sustained release pellets comprising wax-like material

Publications (1)

Publication Number Publication Date
ATE476176T1 true ATE476176T1 (de) 2010-08-15

Family

ID=39649304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08743631T ATE476176T1 (de) 2007-03-02 2008-02-29 Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung

Country Status (10)

Country Link
US (2) US10888521B2 (de)
EP (1) EP2144599B1 (de)
JP (3) JP5452236B2 (de)
CN (1) CN101652128B (de)
AT (1) ATE476176T1 (de)
AU (1) AU2008223091B2 (de)
CA (1) CA2678367C (de)
DE (1) DE602008002073D1 (de)
ES (1) ES2350029T3 (de)
WO (1) WO2008109462A2 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
ITPD20070274A1 (it) * 2007-08-08 2009-02-09 Sanypet S P A Crocchetta per animali e metodo per la sua produzione
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
WO2011080570A2 (en) * 2009-12-29 2011-07-07 Micro Labs Limited Extended release pharmaceutical composition comprising linezolid and process for preparing the same
WO2011095314A2 (en) 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
IT1398321B1 (it) * 2010-02-26 2013-02-22 Formevet Spa Ora Formevet Srl Associazione tra un analgesico ad azione centrale e un antinfiammatorio inibitore selettivo della cicloossigenasi 2 per il trattamento dell'infiammazione e del dolore in campo veterinario
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
US20120107393A1 (en) * 2010-10-29 2012-05-03 University Of Tennessee Research Foundation Pellets for Delivery of Biologically Active Substances
LT2637668T (lt) 2010-11-04 2016-09-12 Albireo Ab Ibat inhibitoriai kepenų ligoms gydyti
PL2736495T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
CN102440963A (zh) * 2011-11-29 2012-05-09 北京科信必成医药科技发展有限公司 一种别嘌醇缓释微丸及其制备方法
US10722458B2 (en) 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
EP2785333A4 (de) 2011-12-02 2015-04-01 Pegasus Lab Inc Amphipatische zusammensetzungen mit verzögerter freisetzung auf lipidbasis
CN102716090B (zh) * 2012-01-05 2014-07-16 金陵药业股份有限公司 一种盐酸二甲双胍缓释微丸及其制备方法
CN102590410A (zh) * 2012-01-13 2012-07-18 亚宝药业太原制药有限公司 盐酸氨基葡萄糖胶囊的含量测定方法
CN102579405A (zh) * 2012-01-17 2012-07-18 广州科的信医药技术有限公司 一种盐酸噻氯匹定缓释胶囊及其制备方法
KR101485748B1 (ko) 2012-02-06 2015-01-22 윌리엄 엘. 프리드젠 팜시클로비어 및 셀레콕시브를 포함한, 기능성 신체 증후군에 대한 항바이러스 화합물 및 cox-2 억제제 조합 치료법
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
LT2838512T (lt) * 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
CA2871821C (en) 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102743341B (zh) * 2012-07-28 2014-02-26 西安德天药业股份有限公司 右旋酮洛芬氨丁三醇缓释微粒及其制备方法和缓释制剂
CN103860551A (zh) * 2012-12-10 2014-06-18 鲁南制药集团股份有限公司 含有依托度酸和盐酸曲马多的药物组合物及其应用
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
EP3013790A1 (de) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Verfahren zur herstellung von nepafenac
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CN103432082A (zh) * 2013-08-29 2013-12-11 江苏正大清江制药有限公司 氨基葡萄糖组合物及其制备方法
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
EP3125873B1 (de) 2014-04-04 2020-06-03 Pharmaquest International Center, LLC Zerfallende monolithische tabletten mit modifizierter freisetzung mit quadri-schichtgranulaten mit verlängerter freisetzung
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
MA41124A (fr) * 2014-12-05 2017-10-10 Sun Pharmaceutical Ind Ltd Compositions en suspension à libération prolongée à rétention gastrique
CN105982860B (zh) * 2015-02-11 2020-04-14 北京科信必成医药科技发展有限公司 愈创甘油醚无水吞服掩味颗粒
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10441605B2 (en) * 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP2019523275A (ja) * 2016-07-26 2019-08-22 アナンド パラチュル，ヴィヴェク 有効成分の徐放性組成物
AU2017310506B2 (en) * 2016-08-11 2019-11-21 Dmk Pharmaceuticals Corporation Drug compositions
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
CN107802610B (zh) * 2017-11-22 2020-10-20 乐普药业股份有限公司 一种单硝酸异山梨酯缓释片及制备方法
WO2019113493A1 (en) 2017-12-08 2019-06-13 Adamis Pharmaceuticals Corporation Drug compositions
US11471386B2 (en) 2017-12-29 2022-10-18 Conopco, Inc. Non-spherical microcapsule
EP3731802B1 (de) 2017-12-29 2021-10-20 Unilever Global IP Limited Asphärische mikrokapsel
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MY209425A (en) 2018-06-20 2025-07-08 Albireo Ab Crystal modifications of odevixibat
CN108578376A (zh) * 2018-07-27 2018-09-28 广州柏赛罗药业有限公司 性能改善的缓释微丸组合物
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN112912067B (zh) * 2018-08-31 2025-04-04 欧普科爱尔兰环球控股有限公司 儿童剂型、制造和使用方法
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
HRP20230039T1 (hr) 2019-02-06 2023-06-09 Albireo Ab Benzotiadiazepinski spojevi i njihova uporaba kao modulatora žučnih kiselina
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
IT201900013473A1 (it) * 2019-07-31 2021-01-31 Vetagro Int S R L Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale
IT201900013449A1 (it) * 2019-07-31 2021-01-31 Vetagro Int S R L Composizione comprendente amminoacidi e una matrice lipidica per animali monogastrici non mammiferi e suo uso
CN110917144A (zh) * 2019-11-30 2020-03-27 江苏艾兰得营养品有限公司 一种骨架型维生素c缓释微丸及其制备方法
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
ES3029063T3 (en) 2019-12-04 2025-06-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
CN110898036A (zh) * 2019-12-18 2020-03-24 乐普制药科技有限公司 一种熊去氧胆酸缓释肠溶胶囊及其制备方法
EP4188541B1 (de) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepin-verbindungen und ihre verwendung als gallensäuremodulatoren
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
KR20230136513A (ko) * 2020-12-25 2023-09-26 인벤티아 헬스케어 리미티드 비타민 c의 안정한 서방성 제형 및 이의 제조 방법
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN113791150B (zh) * 2021-09-09 2023-08-11 浙江公正检验中心有限公司 一种用于动物源性食品中头孢类药物残留量的检测方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3908028A (en) * 1973-04-19 1975-09-23 Procter & Gamble Soft drink composition containing paramethoxycinnamaldehyde as a flavoring agent and sweetner
US4166107A (en) * 1978-07-25 1979-08-28 The United States Of America As Represented By The Secretary Of Agriculture Sustained release bolus formulations containing insect growth regulators for control of livestock pests
JP2804048B2 (ja) * 1987-09-11 1998-09-24 イー・アール・スクイブ・アンド・サンズ・インコーポレイテッド 高薬物含量医薬組成物およびその製造法
US4761450A (en) * 1987-12-11 1988-08-02 Baychem International, Inc. Compatible polymer blends useful as melt adhesives
JP2760012B2 (ja) * 1988-12-26 1998-05-28 武田薬品工業株式会社 持続性細粒剤
JPH02193914A (ja) 1989-01-23 1990-07-31 Sumitomo Pharmaceut Co Ltd マトリックス型持続性製剤
GB8913889D0 (en) 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
AU657114B2 (en) * 1991-01-16 1995-03-02 Fmc Corporation Carrier for active agents, and solid dosage forms prepared therewith
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
FI943121L (fi) 1991-12-30 1994-06-29 Fmc Corp Mikrokiteinen selluloosa -sferonisointikoostumus
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5582351A (en) * 1993-08-09 1996-12-10 Tsau; Josef Convenient to use aspartame and method of making
JP3776941B2 (ja) * 1993-12-24 2006-05-24 塩野義製薬株式会社 味覚の改善された顆粒剤及びその製造方法
DE4413350A1 (de) * 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
US5582855A (en) 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
AU701042B2 (en) * 1995-02-28 1999-01-21 Aventisub Llc Pharmaceutical composition for piperidinoalkanol compounds
FR2742659B1 (fr) 1995-12-22 1998-03-13 Pf Medicament Procede de fabrication de minispheres matricielles a liberation prolongee
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
FR2752732B1 (fr) 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
EP0886519A1 (de) 1996-11-01 1998-12-30 Ilex Oncology, Inc. Zubereitung mit verzögerter freisetzung enthaltend dfmo
US6428813B1 (en) * 1997-03-25 2002-08-06 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent pharmaceutical composition
PL347634A1 (en) * 1998-11-12 2002-04-22 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU5060499A (en) * 1999-08-04 2001-03-05 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
WO2001058447A1 (en) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU2001280597A1 (en) * 2000-07-17 2002-01-30 Guilford Pharmaceuticals Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2002035991A2 (en) * 2000-10-30 2002-05-10 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
US6620611B2 (en) * 2001-01-06 2003-09-16 Geovation Technologies, Inc. Solid-chemical composition for sustained release of organic substrates and complex inorganic phosphates for bioremediation
DE50113344D1 (de) 2001-01-31 2008-01-17 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
US20060153908A1 (en) 2002-06-27 2006-07-13 Brian Strong Spherical pellet formulations
JP2004024686A (ja) 2002-06-27 2004-01-29 Nippon Shinyaku Co Ltd 医薬ワックスマトリックスの製法
CN1201736C (zh) * 2002-07-19 2005-05-18 安徽省药物研究所 甲硝唑结肠定位缓释制剂
US20040208936A1 (en) * 2002-07-22 2004-10-21 Roland Chorin Novel compositions
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005055972A2 (en) * 2003-12-09 2005-06-23 Nanon A/S A drug delivery device and a method of producing it
WO2006045152A1 (en) * 2004-10-29 2006-05-04 Mayne Pharma International Pty Ltd Improved tabletting process

Also Published As

Publication number Publication date
CN101652128B (zh) 2012-12-19
AU2008223091A1 (en) 2008-09-12
CA2678367C (en) 2014-07-08
CN101652128A (zh) 2010-02-17
EP2144599B1 (de) 2010-08-04
US20210113469A1 (en) 2021-04-22
EP2144599A2 (de) 2010-01-20
US10888521B2 (en) 2021-01-12
ES2350029T3 (es) 2011-01-17
WO2008109462A3 (en) 2008-12-24
HK1141441A1 (en) 2010-11-12
AU2008223091B2 (en) 2014-04-24
JP2016000728A (ja) 2016-01-07
JP2010520226A (ja) 2010-06-10
DE602008002073D1 (de) 2010-09-16
JP2014055158A (ja) 2014-03-27
CA2678367A1 (en) 2008-09-12
US20080220079A1 (en) 2008-09-11
JP5452236B2 (ja) 2014-03-26
WO2008109462A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
ATE476176T1 (de) Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
CY1118040T1 (el) Συνθεσεις για πνευμονικη απελευθερωση μακροχρονιως-δρωντων μουσκαρινικων ανταγωνιστων και μακροχρονιως-δρωντων αγωνιστων β2 αδρενεργικων υποδοχεων και συσχετιζομενες μεθοδοι και συστηματα
AR114143A2 (es) Formulaciones de comprimidos revestidos
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
WO2009117130A3 (en) Extended release forumulation containing a wax
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
MX2009000320A (es) Formulaciones de liberacion controlada.
AR082493A1 (es) Formulaciones a base de nalbufina, y sus utilizaciones
WO2007067044A3 (en) Modified active-ingredient-containing pellets/capsules
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
AR065096A1 (es) Preparacion solida
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
UA88477C2 (ru) Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
ECSP099463A (es) Agentes para combatir parásitos en animales
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
BRPI0814891A2 (pt) Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo.
MX2012013021A (es) Formulaciones resistentes a alcohol.
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
UA100850C2 (ru) Средство для борьбы с паразитами на животных
CL2007003451A1 (es) Composicion farmaceutica solida oral que comprende un principio activo y polivinilpirrolidona (pvp) entre 1,0-25%, cpaa entre 0,5-10%, el principio activo consiste en una sal hidrosoluble de metal alcalino, de metal alcalino-terreo, una sal de mezcla

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties